File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Increase risk of HBeAg-negative chronic hepatitis B with older age at HBeAg seroconversion

TitleIncrease risk of HBeAg-negative chronic hepatitis B with older age at HBeAg seroconversion
Authors
Issue Date2009
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The 44th Annual Meeting of the European Association for the Study of the Liver (The International Liver Congress™ 2009), Copenhagen, Denmark, 22–26 April 2009. In Journal of Hepatology, 2009, v. 50 suppl. 1, p. S137 How to Cite?
AbstractBackground: Recent evidence suggests that delayed HBeAg seroconversion is associated with poorer outcome. We aim to determine the incidence of HBeAg-negative chronic hepatitis B (CHB) according to the age at which HBeAg seroconversion occurs. Methods: Chronic hepatitis B patients with natural HBeAg seroconversion and over 12 months follow-up after HBeAg-seroconversion, and without complications, were included. Patients were followed 3−6 monthly with liver biochemistry. HBV DNA and liver stiffness measurements by transient elastography were determined at the time of last follow-up. HBeAgnegative CHB was defined as a combination of ALT elevation above the upper limit of normal on more than one occasion for the entire duration of follow-up after HBeAg seroconversion, and HBV DNA >5 log copies/mL. Results: In total, 228 patients were included with a median follow-up (after HBeAg seroconversion) of 103 months (range, 12–247), of which 118 (52%) were male. The median age was 42 years (range, 21−74). The median age at HBeAg-seroconversion was 32 years (range, 6−64). Seventy-five (33%) and 137 (60%) patients had HBV DNA >5 log and >4 log copies/mL respectively. HBeAg-negative CHB was identified in 51 (22%) patients. In patients with evidence of HBeAg-negative CHB, the median age at HBeAg conversion was significantly higher compared to those with persistently normal ALT or HBV DNA <5 log copies/mL (38 vs 31 years respectively, p<0.001). In patients who seroconverted at age 20, 21−30, 31−40, 41−50, and >50, the rate of HBeAg-negative CHB was 12%, 15%, 21%, 39%, and 75% respectively (p = 0.002). There was no significant difference between males and females with respect to the age at HBeAg seroconversion (34 vs 32 years respectively, p = 0.90), and rate of HBeAg-negative CHB (25% vs 19% respectively, p = 0.25). Patients with HBeAg-negative CHB had higher median liver stiffness compared to those with persistently normal ALT or HBV DNA level <5 log copies/mL (9.0 vs 5.5 kPa respectively, p<0.001). Conclusion: In Asian patients, older age at HBeAg seroconversion, but not gender, was associated with higher rate of HBeAg-negative chronic hepatitis B. Patients with HBeAg-negative CHB had a higher liver stiffness compared to those without evidence of active disease.
Persistent Identifierhttp://hdl.handle.net/10722/62379
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570

 

DC FieldValueLanguage
dc.contributor.authorFung, JYY-
dc.contributor.authorLai, CL-
dc.contributor.authorWong, DKH-
dc.contributor.authorYuen, JCH-
dc.contributor.authorYuen, RMF-
dc.date.accessioned2010-07-13T03:59:59Z-
dc.date.available2010-07-13T03:59:59Z-
dc.date.issued2009-
dc.identifier.citationThe 44th Annual Meeting of the European Association for the Study of the Liver (The International Liver Congress™ 2009), Copenhagen, Denmark, 22–26 April 2009. In Journal of Hepatology, 2009, v. 50 suppl. 1, p. S137-
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/62379-
dc.description.abstractBackground: Recent evidence suggests that delayed HBeAg seroconversion is associated with poorer outcome. We aim to determine the incidence of HBeAg-negative chronic hepatitis B (CHB) according to the age at which HBeAg seroconversion occurs. Methods: Chronic hepatitis B patients with natural HBeAg seroconversion and over 12 months follow-up after HBeAg-seroconversion, and without complications, were included. Patients were followed 3−6 monthly with liver biochemistry. HBV DNA and liver stiffness measurements by transient elastography were determined at the time of last follow-up. HBeAgnegative CHB was defined as a combination of ALT elevation above the upper limit of normal on more than one occasion for the entire duration of follow-up after HBeAg seroconversion, and HBV DNA >5 log copies/mL. Results: In total, 228 patients were included with a median follow-up (after HBeAg seroconversion) of 103 months (range, 12–247), of which 118 (52%) were male. The median age was 42 years (range, 21−74). The median age at HBeAg-seroconversion was 32 years (range, 6−64). Seventy-five (33%) and 137 (60%) patients had HBV DNA >5 log and >4 log copies/mL respectively. HBeAg-negative CHB was identified in 51 (22%) patients. In patients with evidence of HBeAg-negative CHB, the median age at HBeAg conversion was significantly higher compared to those with persistently normal ALT or HBV DNA <5 log copies/mL (38 vs 31 years respectively, p<0.001). In patients who seroconverted at age 20, 21−30, 31−40, 41−50, and >50, the rate of HBeAg-negative CHB was 12%, 15%, 21%, 39%, and 75% respectively (p = 0.002). There was no significant difference between males and females with respect to the age at HBeAg seroconversion (34 vs 32 years respectively, p = 0.90), and rate of HBeAg-negative CHB (25% vs 19% respectively, p = 0.25). Patients with HBeAg-negative CHB had higher median liver stiffness compared to those with persistently normal ALT or HBV DNA level <5 log copies/mL (9.0 vs 5.5 kPa respectively, p<0.001). Conclusion: In Asian patients, older age at HBeAg seroconversion, but not gender, was associated with higher rate of HBeAg-negative chronic hepatitis B. Patients with HBeAg-negative CHB had a higher liver stiffness compared to those without evidence of active disease.-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatology-
dc.rights© <year>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.titleIncrease risk of HBeAg-negative chronic hepatitis B with older age at HBeAg seroconversion-
dc.typeConference_Paper-
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0168-8278&volume=50&issue=Suppl 1&spage=S137&epage=&date=2009&atitle=Increase+risk+of+HBeAg-negative+chronic+hepatitis+B+with+older+age+at+HBeAg+seroconversionen_HK
dc.identifier.emailFung, JYY: jfung@HKUCC.hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hku.hk-
dc.identifier.emailWong, DKH: danywong@hku.hk-
dc.identifier.emailYuen, JCH: jchyuen@HKUCC.hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hkucc.hku.hk-
dc.identifier.authorityFung, JYY=rp00518-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityWong, DKH=rp00492-
dc.identifier.authorityYuen, RMF=rp00479-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0168-8278(09)60361-5-
dc.identifier.hkuros161375-
dc.identifier.hkuros158499-
dc.identifier.volume50-
dc.identifier.issuesuppl. 1-
dc.identifier.spageS137-
dc.identifier.epageS137-
dc.publisher.placeThe Netherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats